Donor cell transplantation for myocardial disease: does it complement current pharmacological therapies?
Heart failure secondary to ischemic heart disease, hypertension, and myocardial infarction is a common cause of death in developed countries. Although pharmacological therapies are very effective, poor prognosis and shorter life expectancy of heart disease patients clearly indicate the need for alternative interventions to complement the present therapies. Since the progression of heart disease is associated with the loss of myocardial cells, the concept of donor cell transplantation into host myocardium is emerging as an attractive strategy to repopulate the damaged tissue. To this end, a number of donor cell types have been tested for their ability to increase the systolic function of diseased hearts in both experimental and clinical settings. Although initial clinical trials with bone marrow stem cells are encouraging, long-term consequences of such interventions are yet to be rigorously examined. While additional laboratory studies are required to address several issues in this field, there is also a clear need for further characterization of drug interactions with donor cells in these interventions. Here, we provide a brief summary of current pharmacological and cell-based therapies for heart disease. Further, we discuss the potential of various donor cell types in myocardial repair, mechanisms underlying functional improvement in cell-based therapies, as well as potential interactions between pharmacological and cell-based therapies.
McMullen
Nichole M
NM
Department of Pharmacology, Sir Charles Tupper Medical Building, Dalhousie University, Halifax, Canada.
Pasumarthi
Kishore B S
KB
D053687:Adult Stem Cells / Q000166:cytology / Q000187:drug effects / Q000637:transplantation*; D000818:Animals; D009202:Cardiomyopathies / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002454:Cell Differentiation; D017690:Cell Transplantation / Q000379:methods*; D053595:Embryonic Stem Cells / Q000166:cytology / Q000187:drug effects / Q000637:transplantation*; D006801:Humans; D032383:Myocytes, Cardiac / Q000166:cytology / Q000187:drug effects / Q000637:transplantation*; D044968:Regenerative Medicine / Q000639:trends; D033581:Stem Cell Transplantation / Q000379:methods; D016896:Treatment Outcome
D002317:Cardiovascular Agents